Gaumond Simonetta I, Beraja Gabriela E, Kamholtz Isabella, Ferrari Lina M, Mahmoud Rami H, Jimenez Joaquin J
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Cancers (Basel). 2025 Jan 26;17(3):411. doi: 10.3390/cancers17030411.
BACKGROUND/OBJECTIVES: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer.
This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis.
Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin-paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity.
Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.
背景/目的：卵巢癌是女性中第五大常见癌症，预计2024年将有19,680例新发病例。辅助化疗仍然是上皮性卵巢癌的标准治疗方法，但经常与不良事件相关，如化疗引起的脱发（CIA）。CIA是一种特别令人苦恼的副作用，会显著影响患者的身体形象、自尊和生活质量。不幸的是，卵巢癌患者中的CIA仍未得到充分研究。
本范围综述分析了PubMed和EMBASE索引的研究，这些研究调查了卵巢癌患者中CIA的发生率、严重程度和机制。纳入18项研究进行分析。
我们的分析确定铂类化合物、紫杉烷和拓扑异构酶I抑制剂是与严重脱发相关性最强的药物，特别是在联合方案中，如卡铂-紫杉醇（CP）以及环磷酰胺、阿霉素和顺铂（CAP）。在单一疗法中，包括紫杉醇和多西他赛在内的紫杉烷导致CIA的风险最高。接受吉西他滨或聚乙二醇化脂质体阿霉素治疗的患者出现轻至中度脱发。给药方案和既往化疗暴露等其他因素也会显著影响CIA的严重程度。
鉴于CIA对心理社会的深远影响，在不影响治疗效果的情况下优化治疗方案以降低脱发严重程度至关重要。这些发现提供了可能指导未来治疗策略以改善患者预后和生活质量的见解。
